DUOnco

DUOnco

TM

商标

Bone : First CE marked IA algorithm for automatic detection of bone lesions on

骨骼：首个CE认证的IA算法，用于自动检测骨骼病变。

CT scan

CT扫描

The first CE-marked IA for the detection of bones lesions

第一个用于检测骨病变的CE认证IA

A world premier : an innovate solution expected of the entire medical profession

全球首创：整个医疗行业期待的创新解决方案

Enhancement of DUOnco

DUOnco的增强

TM

商标

, IA range for integration into medical imaging systems

，IA范围用于集成到医学成像系统中

Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate solution in IA, the world's first dedicated IA to the detection and localization of bone lesions on thoraco-abdomino-pelvic (TAP) scans..

法国蒙彼利埃，2025年3月18日。Intrasense（ISIN：FR0011179886 – 股票代码：ALINS），法国医疗影像解决方案专家，利用人工智能辅助和保障诊断、决策及治疗随访；与全球医疗影像领域的领导者Guerbet（FR0000032526 GBT）以及Intrasense（FR0011179886 - ALINS）联合宣布，DUOnco™ Bone已获得MDR（医疗器械法规）CE认证。这是一款创新的人工智能解决方案，也是全球首个专注于胸部-腹部-骨盆（TAP）扫描中骨病变检测与定位的人工智能技术。

On this occasion,

在这种情况下，

Alexandre Salvador, Intrasense’s CEO

亚历山大·萨尔瓦多，Intrasense首席执行官

, says :

，说道：

'This CE marking is a key milestone that validates Intrasense and Guerbet's expertise in developing AI solutions for reference medical imaging in oncology. Together, we are developing and bringing to market ever more effective solutions tailored to the needs of the field. DUOnco™ Bone strengthens our product portfolio by offering radiologists an accurate and effective tool for detecting bone lesions.

“这个CE标志是一个关键的里程碑，验证了Intrasense和Guerbet在开发肿瘤学参考医学影像人工智能解决方案方面的专业性。我们正在共同努力，开发并推出更加有效的、符合该领域需求的解决方案。DUOnco™ Bone通过为放射科医生提供一种检测骨病变的准确且有效的工具，进一步增强了我们的产品组合。

Its flexibility as a stand-alone solution also enables us to enrich the offerings of our partners, whether PACS vendors or marketplace platforms, by bringing differentiating added value.'.

其作为独立解决方案的灵活性还使我们能够通过带来差异化的附加价值，丰富我们的合作伙伴（无论是PACS供应商还是市场平台）的产品 offerings。

A major impact for oncology imaging

对肿瘤成像产生重大影响

Early detection of bone lesions is a major clinical challenge in oncology, as these lesions are frequently under-detected due to the large volume of images to be analyzed and the complexity of bone structures. Despite technological advances in medical imaging, studies show that up to 30% of bone metastases are not detected on CT scans.

早期检测骨病变是肿瘤学中的主要临床挑战，因为由于需要分析的图像量大以及骨骼结构复杂，这些病变经常被漏检。尽管医学影像技术有所进步，但研究表明，多达30%的骨转移在CT扫描中未被发现。

1

1

, making bone one of the most frequent sites of diagnostic errors in CT imaging

，使骨骼成为CT成像中最常出现诊断错误的部位之一

2

2

.

。

DUOnco™ Bone, co-developed by Intrasense and Guerbet, is the first CE-marked AI solution for detecting bone lesions on CT scan images. Designed to automatically analyze TAP (thorax-abdomen-pelvis) scanner images and detect bone lesions, the solution relies on cutting-edge deep learning algorithms to accurately identify suspicious anomalies and provide their 3D coordinates to clinicians.

DUOnco™ Bone是由Intrasense和Guerbet共同开发的首款获得CE认证的用于检测CT扫描图像中骨病变的人工智能解决方案。该解决方案旨在自动分析胸腹盆腔（TAP）扫描图像并检测骨病变，依托前沿的深度学习算法，精准识别可疑异常，并向临床医生提供其三维坐标。

DUOnco™ Bone optimizes radiologists' workflow by and speeds up the interpretation of results. This technological advance enables faster and safer patient management, particularly by facilitating early detection of bone lesions..

DUOnco™ Bone优化了放射科医生的工作流程，加快了结果的解读。这项技术进步能够实现更快、更安全的患者管理，特别是通过促进骨骼病变的早期检测。

With DUOnco™ Bone, healthcare establishments benefit from cutting-edge diagnostic assistance technology, improving the productivity of radiologists, the reliability of analyses and the quality of care provided to patients. From a strategic standpoint, this breakthrough reinforces Intrasense and Guerbet's positioning as major players in AI for medical imaging, paving the way for new partnership opportunities and international deployments.

通过DUOnco™ Bone，医疗机构受益于尖端的诊断辅助技术，提高了放射科医生的工作效率、分析的可靠性以及提供给患者的护理质量。从战略角度来看，这一突破巩固了Intrasense和Guerbet作为医学影像人工智能领域重要参与者的地位，为新的合作机会和国际部署铺平了道路。

Enhancement of the DUOnco™ high medical value AI range

DUOnco™ 高医疗价值 AI 系列的增强

DUOnco™ solutions integrate seamlessly into existing workflows, without changing user habits. Designed for maximum flexibility, the DUOnco™ range is also available as a stand-alone solution: its high medical value artificial intelligence algorithms in oncology can be integrated into third-party solutions, adapting to the needs of healthcare facilities and software publishers..

DUOnco™ 解决方案能够无缝融入现有工作流程，无需改变用户习惯。DUOnco™ 系列设计注重最大灵活性，也可作为独立解决方案使用：其高医学价值的肿瘤学人工智能算法可以集成到第三方解决方案中，适应医疗机构和软件开发商的需求。

Compatible with PACS systems, third-party viewers, marketplaces and other medical imaging infrastructures, DUOnco™ facilitates deployment, without technical constraints or disruption to clinical workflows, for rapid adoption and seamless integration into existing environments.

与PACS系统、第三方查看器、市场及其他医疗影像基础设施兼容，DUOnco™便于部署，不受技术限制，也不会干扰临床工作流程，可快速采用并无缝集成到现有环境中。

Liflow

利福ロー

®

®

: native integration for optimized management

：原生集成以实现优化管理

At the same time, the DUOnco™ range integrates natively with Liflow

同时，DUOnco™ 系列与 Liflow 原生集成。

®

®

, Intrasense's oncology imaging platform. This integration guarantees seamless examination management and optimal centralization of results in a unified environment, accessible from a single tool.

，Intrasense的肿瘤成像平台。这种集成保证了在统一环境中无缝管理检查，并优化结果的集中化，可通过单一工具访问。

The addition of DUOnco™ Bone to the Liflow®

将DUOnco™ Bone添加到Liflow®中

3

3

ecosystem represents a major strategic advance, strengthening Intrasense's offering and optimizing the diagnosis of bone lesions. This innovation marks a key step towards ever more efficient and integrated AI, supporting radiologists in their day-to-day work. Other solutions, notably in the field of pancreatic imaging, will soon complete this package to offer even broader clinical coverage..

生态系统代表了一项重大的战略进步，增强了Intrasense的产品 offerings，并优化了骨病变的诊断。这一创新标志着迈向更高效、更集成的人工智能的关键一步，支持放射科医生的日常工作。其他解决方案，特别是在胰腺成像领域的解决方案，将很快完善这一揽子方案，以提供更广泛的临床覆盖。

Prof. Nathalie Lassau, Professor of Radiology at the University of Paris-Saclay and radiologist at Gustave Roussy

巴黎萨克雷大学放射学教授、古斯塔夫·鲁西放射科医生娜塔莉·拉索教授

, states:

，状态：

'In our practice, the evaluation of bone metastases is a critical step that requires great precision due to the complexity of the examinations. DUOnco™ Bone, integrated with Liflow

“在我们的实践中，骨转移的评估是一个关键步骤，由于检查的复杂性，需要极高的精确度。DUOnco™ Bone与Liflow整合，

®

®

, will provide invaluable support by optimizing our analysis of TAP scanner images and facilitating our decision-making With this intelligent assistance, we have a tool that will improve our efficiency to contribute directly to the optimization of the oncology care pathway.'

“将通过优化我们对TAP扫描图像的分析并促进我们的决策提供无价的支持。有了这种智能辅助，我们就有了一个能够提高效率的工具，直接有助于优化肿瘤诊疗路径。”

About Intrasense

关于 Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries to facilitate and secure diagnosis, decision-making and therapeutic follow-up.

自2004年以来，法国医学影像专家Intrasense在40个国家开发和销售软件平台，以促进和保障诊断、决策和治疗随访。

Myrian

米里安

®

®

, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow

，一种先进的放射学可视化解决方案，为1200家医疗机构提供临床应用，帮助解读所有类型的图像。自2021年以来，Intrasense一直在开发Liflow。

®

®

, a new multidisciplinary and collaborative platform dedicated to oncology, to optimize patient care and follow-up. A digital subsidiary of the Guerbet Group since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives..

，一个致力于肿瘤学的全新多学科协作平台，旨在优化患者护理和随访。自2023年6月起成为Guerbet集团的数字子公司，Intrasense通过在医学影像中集成人工智能算法不断丰富其解决方案。其团队与医疗专业人员密切合作，助力挽救生命。

More information on

更多信息请参见

www.intrasense.fr

www.intrasense.fr

About Guerbet

关于Guerbet

Guerbet is a world leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices and AI-based solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual sales in research and development, with dedicated innovation centers in France and the United States.

Guerbet是医学影像领域的全球领导者，致力于通过创新改善患者护理。凭借近一个世纪的专业经验，公司提供涵盖诊断和介入影像的全面医药产品、医疗器械及基于人工智能的解决方案。Guerbet将其年销售额的9%投入研发，并在法国和美国设有专门的创新中心。

The company (GBT) is listed on Euronext Paris and has reported sales of 841 million euros in 2024..

该公司（GBT）在巴黎泛欧交易所上市，2024年报告的销售额为8.41亿欧元。

For further information:

更多信息请访问：

www.guerbet.com

www.guerbet.com

Contacts

联系人

INTRASENSE

内在感知

Chargée des communications

通讯负责人

Salomé Sylvestre

萨洛梅·西尔维斯特

Phone: +334 67 13 01 30

电话：+334 67 13 01 30

investisseurs@intrasense.fr

投资者@intrasense.fr

GUERBET

格贝特

Corporate Communications Manager

企业传播经理

Matthieu Bruneau

马修·布吕诺

Phone: +336 78 83 89 96

电话：+336 78 83 89 96

matthieu.bruneau@guerbet.com

马修·布吕诺@格贝特公司

SEITOSEI.ACTIFIN

SEITOSEI.ACTIFIN

Relations Analystes & Investisseurs

分析师与投资者关系

Foucauld Charavay

福柯·沙拉瓦伊

Phone: +336 37 83 33 19

电话：+336 37 83 33 19

intrasense@seitosei-actifin.com

intrasense@seitosei-actifin.com

Relations Presse

媒体关系

Isabelle Dray

伊莎贝尔·德拉伊

Phone: +331 56 88 11 29

电话：+331 56 88 11 29

isabelle.dray@seitosei-actifin.com

isabelle.dray@seitosei-actifin.com

1 Ha JY, Jeon KN, Bae K, Choi BH. Effect of Bone Reading CT software on radiologist performance in detecting bone metastases from breast cancer. Br J Radiol 2017; 90: 20160809

1 Ha JY, Jeon KN, Bae K, Choi BH。骨阅读CT软件对放射科医生检测乳腺癌骨转移性能的影响。《英国放射学杂志》2017；90：20160809

2 Kasalak Ö et al. Work overload and diagnostic errors in radiology. European Journal of Radiology 2023, Volume 167, 111032

2 Kasalak Ö 等。放射学中的工作过载与诊断错误。《欧洲放射学杂志》2023年，第167卷，111032

3 Available in the upcoming Liflow

3 即将在 Liflow 中提供

®

®

3.0 release

3.0版本发布

Attachment

附件

PR_Duonco-bone_EN

PR_Duonco-bone_EN